GET THE APP

European Journal of Clinical Oncology

ISSN - 2732-2654

Abdel-Moneim Mahmoud Ali Osman

Abdel-Moneim Mahmoud Ali Osman, PhD
Professor, Department of Pharmacology
Cairo University, Egypt

Biography

Abdel-Moneim Mahmoud Ali Osman has received his Ph.D. in Pharmacology, University of Amsterdam, during the period of 1985. Currently, He is working as Deputy Chairman of department of Pharmacology, College of Medicine, KAU, Jeddah (2012-To 2018). His research interest includes molecular biology of brain tumors, for molecular diagnosis in tissue culture Technique (The Netherlands Cancer institute Hospital) dealing with the growth of human tumour cells, glucocorticoid receptor determination,tumour cell cycle phase determination using flowcytometer and tumour cell cycle phase separation using  gravity sedimentation chamber Good experience in screening the potentially anticancer agents and the interaction between anticancer drugs and other drugs using different   tumour cell lines. He is serving as an editorial member of several reputed journals like Cancer Translational Medicine. He has authored 98 research articles. He has technical skills in tumour cell cycle phase determination using flowcytometer and tumour cell cycle phase separation using  gravity sedimentation chamber. Good experience in using HPLC technique for determination of plasma level of some anticancer drugs (Free University Hospital, The Netherland) a routine used for the treatment of some cancer patients. Also the using of the same technique for determination of some markers used for diagnosis and follow up of neuroblastoma patients.     

Research Interest

His research interest includes molecular biology of brain tumors, for molecular diagnosis in tissue culture Technique (The Netherlands Cancer institute Hospital) dealing with the growth of human tumour cells, glucocorticoid receptor determination,tumour cell cycle phase determination using flowcytometer and tumour cell cycle phase separation using  gravity sedimentation chamber Good experience in screening the potentially anticancer agents and the interaction between anticancer drugs and other drugs using different   tumour cell lines.

Top